U.S. Markets close in 6 hrs 3 mins

Allergan plc (AGN)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
205.12-4.88 (-2.32%)
As of 9:57AM EDT. Market open.
People also watch
BIIBCELGVRXGILDREGN
Full screen
Previous Close210.00
Open208.31
Bid205.24 x 100
Ask205.37 x 100
Day's Range203.89 - 208.50
52 Week Range184.50 - 256.80
Volume784,340
Avg. Volume2,103,382
Market Cap68.57B
Beta1.24
PE Ratio (TTM)6.25
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.80 (1.30%)
Ex-Dividend Date2017-08-16
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com21 hours ago

    Allergan: Just How Far Will Big Pharma Go To Protect Its Patents?

    Specialty drug maker Allergan (AGN) raised more than a few eyebrows this month when news broke of the deal it made with the Saint Regis Mohawk Tribe of upstate New York to protect patents for one of its blockbuster drugs. In fact, one of Wall Street biggest drug analysts cited the deal as one of three reasons it has downgraded Allergan’s stock and slashed its price target. Allergan decided earlier this month to transfer ownership of the patents protecting the dry eye treatment Restasis, Allergan’s second biggest selling drug, to the tribe to prevent the scrutiny of the U.S. Patent & Trademark Office.

  • See what the IHS Markit Score report has to say about Allergan plc.
    Markityesterday

    See what the IHS Markit Score report has to say about Allergan plc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Apple Likes the Patent ‘Death Squad.’ Allergan Pays to Avoid It
    Bloombergyesterday

    Apple Likes the Patent ‘Death Squad.’ Allergan Pays to Avoid It

    Allergan Plc’s decision to pay a Native American tribe $15 million a year rather than let one of its blockbuster drugs be scrutinized by the U.S. Patent & Trademark Office is part of a backlash against an ...